PF-06869206

PF-06869206

Application

PF-06869206 has been used to selectively inhibit the activity of sodium-phosphate cotransporter 2a (NaPi2a).

Biochem/physiol Actions

PF-06869206 is a selective inhibitor against sodium-phosphate cotransporter 2A (NaPi-2a, NaPi-Iia, Na+/Pi cotransporter 2A, Na+-dependent phosphate cotransporter 2A).

PF-06869206 may be used to treat patients with mineral and hormonal derangements linked with increased cardiovascular risk in chronic kidney disease. This drug might also improve urinary phosphate excretion. PF-06869206 has an ability to decrease phosphate uptake in human embryonic kidney (HEK) cells transfected with mouse or rat renal sodium-dependent phosphate transporter genes (Npt2a).

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3573856 PF-06869206 white to beige SIGMA-ALDRICH room temp DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£498.64 (exc VAT) per 25MG
-
+
3573857 PF-06869206 white to beige SIGMA-ALDRICH room temp DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£137.75 (exc VAT) per 5MG
-
+